



erlotinib


Fractional polynomial (0, 0)




Fractional polynomial (0, 1)



Gompertz



Weibull



Month

— JAGS — R

gefitinib

Fractional polynomial (0, 0)

Fractional polynomial (0, 1)

Gompertz

Weibull

Progression-free survival

0

20

40

60

Month

0





20

40

60


JAGS

R




afatinib


Fractional polynomial (0, 0)




Fractional polynomial (0, 1)



Gompertz



Weibull



— JAGS — R





dacomitinib

Fractional polynomial (0, 0)

Fractional polynomial (0, 1)

Gompertz

Weibull





— JAGS — R

osimertinib



Fractional polynomial (0, 0)

Fractional polynomial (0, 1)



Gompertz

Weibull



— JAGS — R